

FORM PTO-1390  
(REV. 11-2000)

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

AGENCY'S DOCKET NUMBER  
Z70598-1

**TRANSMITTAL LETTER TO THE UNITED STATES  
DESIGNATED/ELECTED OFFICE (DO/EO/US)  
CONCERNING A FILING UNDER 35 U.S.C. 371**

U.S. APPLICATION NO. (If known, see 37 CFR 1.5

**10/088856**

INTERNATIONAL APPLICATION NO.  
PCT/GB00/03593

INTERNATIONAL FILING DATE  
September 19, 2000

PRIORITY DATE CLAIMED  
September 21, 1999

TITLE OF INVENTION

Therapeutic Quinazoline Derivatives

APPLICANT(S) FOR DO/EO/US

ASTRAZENECA AB

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1.  This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2.  This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3.  This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below.
4.  The US has been elected by the expiration of 19 months from the priority date (Article 31).
5.  A copy of the International Application as filed (35 U.S.C. 371(c)(2))
  - a.  is attached hereto (required only if not communicated by the International Bureau).
  - b.  has been communicated by the International Bureau.
  - c.  is not required, as the application was filed in the United States Receiving Office (RO/US).
6.  An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).
  - a.  is attached hereto.
  - b.  has been previously submitted under 35 U.S.C. 154(d)(4).
7.  Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))
  - a.  are attached hereto (required only if not communicated by the International Bureau).
  - b.  have been communicated by the International Bureau.
  - c.  have not been made; however, the time limit for making such amendments has NOT expired.
  - d.  have not been made and will not be made.
8.  An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371 (c)(3)).
9.  An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).
10.  An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).

**Items 11 to 20 below concern document(s) or information included:**

11.  An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
12.  An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
13.  A **FIRST** preliminary amendment.
14.  A **SECOND** or **SUBSEQUENT** preliminary amendment.
15.  A substitute specification.
16.  A change of power of attorney and/or address letter.
17.  A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 35 U.S.C. 1.821 - 1.825.
18.  A second copy of the published international application under 35 U.S.C. 154(d)(4).
19.  A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).
20.  Other items or information:

U.S. APPLICATION NO. (if known, see 37 CFR 1.5) <b>10,08885</b>	INTERNATIONAL APPLICATION NO. PCT/GB00/03593	ATTORNEY'S DOCKET NUMBER Z70598-1
--	---	--------------------------------------

21. <input type="checkbox"/> The following fees are submitted: <b>BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)):</b> Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO. . . . . <b>\$1000.00</b>  International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO . . . . . <b>\$860.00</b>  International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO . . . . . <b>\$710.00</b>  International preliminary examination fee (37 CFR 1.482) paid to USPTO but all claims did not satisfy provisions of PCT Article 33(1)-(4) . . . . . <b>\$690.00</b>  International preliminary examination fee (37 CFR 1.482) paid to USPTO and all claims satisfied provisions of PCT Article 33(1)-(4) . . . . . <b>\$100.00</b>  <b>ENTER APPROPRIATE BASIC FEE AMOUNT =</b>	<b>CALCULATIONS PTO USE ONLY</b>         \$ 860.00
--	---

Surcharge of \$130.00 for furnishing the oath or declaration later than  20  30 months from the earliest claimed priority date (37 CFR 1.492(e)).

CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE	\$	
Total claims	30 - 20 =	10	x \$18.00	\$ 180.00	
Independent claims	- 3 =		x \$80.00	\$	
MULTIPLE DEPENDENT CLAIM(S) (if applicable)			+ \$270.00	\$	

**TOTAL OF ABOVE CALCULATIONS =** \$

Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by 1/2. + \$

**SUBTOTAL =** \$

Processing fee of \$130.00 for furnishing the English translation later than  20  30 months from the earliest claimed priority date (37 CFR 1.492(f)). \$

**TOTAL NATIONAL FEE =** \$

Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property + \$ 40.00

**TOTAL FEES ENCLOSED =** \$ 1080

Amount to be refunded:	\$
charged:	\$

- a.  A check in the amount of \$ \_\_\_\_\_ to cover the above fees is enclosed.
- b.  Please charge my Deposit Account No. 26-0166 in the amount of \$ 1080.00 to cover the above fees. A duplicate copy of this sheet is enclosed.
- c.  The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 26-0166. A duplicate copy of this sheet is enclosed.
- d.  Fees are to be charged to a credit card. **WARNING:** Information on this form may become public. **Credit card information should not be included on this form.** Provide credit card information and authorization on PTO-2038.

**NOTE:** Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137 (a) or (b)) must be filed and granted to restore the application to pending status

SEND ALL CORRESPONDENCE TO:

AstraZeneca Pharmaceuticals  
Global Intellectual Property  
Patent Administrator  
1800 Concord Pike  
P.O. Box 15437

\_\_\_\_\_  
SIGNATURE  
George A. Gilbert

\_\_\_\_\_  
NAME  
35,881

10/088856  
1010 Rec'd PCT/PTO 21 MAR 2002

Certificate of Express Mail (37 CFR 1.10)

Label No. EF227334538US

I hereby certify that the attached papers or fee are being deposited with the United States Postal Service "express Mail Post Office to Addressee" service on the date show below in an envelope addressed to Box PCT Application, Assistant Commissioner for Patents, Washington, DC 20231.

3-21-02  
(Date)

Marie M. Greloch  
(Printed Name)

Marie Greloch  
(Signature)

AstraZeneca Pharmaceuticals  
Docket No. 70598-1

PCT Application of: MORTLOCK, Andrew Austen  
KEEN, Nicholas John

Filed as a US National Phase Application of  
International Application No. PCT/GB00/03593  
Filed September 19, 2000

For: **THERAPEUTIC QUINAZOLINE DERIVATIVES**

Attached please find:

- 1) Transmittal letter concerning a filing under 35 U.S.C. 371 (Form PTO-1390, in duplicate)
- 2) Substitute Form PTO-1449 with References
- 3) Information Disclosure Statement
- 4) Copy of the International Application
- 5) Copy of the International Search Report
- 6) Declaration and Power of Attorney
- 7) Assignment with Separate Cover Sheet
- 8) International Preliminary Examination Report

Respectfully submitted,

George A. Gilbert

George A. Gilbert  
Attorney for Applicants  
Reg. No. 35,881  
Telephone: (302) 886-3887

Dated: 3-21-02